Reduction in thyroid perfusion after bevacizumab treatment

Thyroid

Volumn 23, Issue 10, 2013, Pages 1329-1330

  Van Der Veldt, Astrid A M ^a   Lammertsma, Adriaan A ^a   Smit, Egbert F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LEVOTHYROXINE; PLACENTAL GROWTH FACTOR; SUNITINIB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER PATIENT; COLORECTAL CANCER; COMPETITIVE INHIBITION; DRUG HALF LIFE; HUMAN; HYPOTHYROIDISM; KIDNEY CANCER; LETTER; LUNG NON SMALL CELL CANCER; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; THYROID DISEASE; THYROID FUNCTION; THYROID GLAND; TISSUE PERFUSION;

HUMANS; INDOLES; PROTEIN KINASE INHIBITORS; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; THYROID DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84884616414     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0147     Document Type: Letter

References (10)

1. Makita N, Iiri T 2013 Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 23: 151-159.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bu-kowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124.
3. Ferrara N, Gerber HP, LeCouter J 2003 The biology of VEGF and its receptors. Nat Med 9:669-676.
4. Ferrara N, Hillan KJ, Gerber HP, Novotny W 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400.
5. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM 2006 VEGF-dependent plasticity of fenes-trated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:H560-H576.
6. Van der Veldt AA, Hendrikse NH, Harms H, Comans EF, Postmus PE, Smit EF, Lammertsma AA, Lubberink M 2010 Quantitative parametric perfusion images using oxygen-15 labeled water and a clinical PET-CT scanner: test-retest variability in lung cancer. J Nucl Med 51:1684-1690.
7. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serné EH, Lammertsma AA, Smit EF 2012 Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21:82-91.
8. Van Cruijsen H, Van der Veldt A, Hoekman K 2009 Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Front Biosci 14:2248-2268.
9. Van der Veldt AA, De Boer MP, Boven E, Eringa EC, Van den Eertwegh AJ, Van Hinsbergh VW, Smulders YM, Serné EH 2010 Reduction in skin microvascular density and changes in vessel morphology in patients treated with su-nitinib. Anticancer Drugs 21:439-446.
10. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, VandenDriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG 2001 Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575-583.